drugset / Trial / NCT01225315

Clinical Study to Explore the Efficacy of ACT-129968 in Patients With Partly Controlled Asthma

NCT01225315

Phase 2 Completed 438 enrolled Idorsia Pharmaceuticals Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will assess the efficacy and safety of ACT-129968 in subjects with partly controlled asthma on reliever therapy only.

Timeline

Start
2010-11-01
Primary completion
2012-01-01
Completion
2012-02-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Setipiprant Small molecule 100 mg Oral
Subject Setipiprant Small molecule 500 mg Oral
Subject Setipiprant Small molecule 1000 mg Oral

Indications